- Hardcover: 474 pages
- Publisher: Wiley-Blackwell; 3 edition (March 12, 2012)
- Language: English
- ISBN-10: 0470973765
- ISBN-13: 978-0470973769
- Product Dimensions: 7 x 1.1 x 9.9 inches
- Shipping Weight: 1.9 pounds (View shipping rates and policies)
- Average Customer Review: 1 customer review
- Amazon Best Sellers Rank: #1,616,763 in Books (See Top 100 in Books)
Enter your mobile number or email address below and we'll send you a link to download the free Kindle App. Then you can start reading Kindle books on your smartphone, tablet, or computer - no Kindle device required.
To get the free app, enter your mobile phone number.
Pharmacotherapy of Child and Adolescent Psychiatric Disorders 3rd Edition
Use the Amazon App to scan ISBNs and compare prices.
Step-Up to Medicine
Featured pharmacology resource from Lippincott. See more
Frequently bought together
Customers who bought this item also bought
“Pharmacotherapy of Child and Adolescent Psychiatric Disorders is a book to have available on your desk, not just in your library. It provides ready access to the wealth of practical information and insight for the range of health and mental health professionals. It is highly recommended for trainees and anyone who is prescribing psychotropic medications to the pediatric population and young adults.” (Journal of Clinical Psychiatry, 7 July 2012)
From the Back Cover
This book fulfils an urgent need for an updated text on pediatric psychopharmacology. It takes a unique approach in discussing recent findings within the context of current issues, including economic and political ones. The book covers the emerging question of treating children who do not yet meet diagnostic criteria for psychosis, e.g, schizophrenia or bipolar disorder, but who are deemed to be at high risk. This is an active area of debate: such children are being treated in certain centers, while others reject this completely. The book addresses the antidepressant controversy, the placebo response and unique strategies for delineating this, and ways to optimize the differential between active medication and placebo. It reviews the impact of recent American Heart Association guidelines for monitoring children on stimulants and other psychotropics. It adheres closely to DSM-IV diagnostic criteria throughout. The book describes the use of newly approved drugs such as Lexapro for treating adolescent depression and the novel compound Intuniv. It covers the TADS and CAMS studies, which evaluated the use of SSRIs alone and in combination with cognitive behavioral therapy for adolescent depression. Other topics include treatment of bipolar disorders, the increasing popularity of generic equivalents, combination pharmacotherapy and the potential dangers of psychotropic medications.
- Third edition of the first ever book published on pediatric psychopharmacology from renowned editors.
- Incorporates current developments with regard to SSRIs, their indications and their safety issues, including possible associated suicidal behavior.
- Addresses concerns about cardiovascular side effects of the new stimulant medications available, and compares to other FDA-approved medications for ADHD.
- Features many tables, figures and pictorials, making it highly accessible and reader friendly.
Top customer reviews
The drugs are organized by pharmacological families.
And I loved the last chapter: "combination pharmacotherapy for psychiatric disorders in children and adolescents".
Too bad it haven't neurobiological correlate.